Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells

R J Errington1, S M Ameer-Beg, B Vojnovic

  • 1Department of Medical Biochemistry and Immunology, University of Wales College of Medicine, Cardiff, CF14 4XN, UK. erringtonrj@cardiff.ac.uk

Insights

This study developed advanced microscopy techniques to track anticancer drugs like topotecan (TPT) interacting with DNA in live tumor cells, improving drug discovery and development.

Area of Science:

  • Cellular and Molecular Pharmacology
  • Cancer Therapeutics
  • Advanced Microscopy Techniques

Background:

  • Anticancer drug efficacy relies on interactions with DNA and chromatin.
  • Understanding drug-target dynamics is crucial for developing new therapies.
  • Challenges include transient events, micropharmacokinetics, and cell heterogeneity.

Purpose of the Study:

  • To develop and demonstrate modular tools for quantifying drug targeting dynamics in single cells.
  • To map the interactions of anticancer drugs with DNA in live tumor cells.
  • To enable rational drug development and enhance the drug discovery pipeline.

Main Methods:

  • Integration of two-photon laser scanning microscopy (TPLSM) for subcellular drug tracking.
  • Combination of TPLSM with fluorescence lifetime imaging microscopy (FLIM) to map drug-DNA interactions.
  • Utilizing a two-photon 'dark' DNA binding probe (DRAQ5) as a quenching probe.

Main Results:

  • Successfully mapped the nuclear docking of topotecan (TPT) at specific DNA sites in live breast tumor cells.
  • Demonstrated the use of a novel DNA binding probe to identify drug interaction sites.
  • Provided a method to overcome challenges in studying drug targeting dynamics in situ.

Conclusions:

  • The developed modular kinetic assays offer a powerful approach to study drug targeting in single cells.
  • This technology can be integrated into high-content screening for drug discovery.
  • Future work includes linking drug-target interactions to cellular stress responses.